Velufenacin is an investigational antimuscarinic agent primarily developed for the treatment of overactive bladder (OAB). It works by selectively blocking muscarinic receptors in the bladder, reducing involuntary contractions of the detrusor muscle. This action helps decrease symptoms such as urgency, frequency, and urge incontinence. Due to its high bladder selectivity, velufenacin may offer improved tolerability with fewer systemic side effects like dry mouth or constipation compared to non-selective antimuscarinics. It has been studied in oral formulations and is intended for once-daily dosing, which supports better patient compliance. Although still under clinical investigation, it shows potential as a well-tolerated and effective option for long-term management of OAB.